How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,926 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

or Thrombocytosis 17 Primary Myelofibrosis 18 Genetic Testing for Hematologic Malignancy 18 Minimal Residual Disease (MRD) Genetic Testing 18 Solid Tumor Testing 19 NTRK Fusion Testing 19 PIK3CA Testing 20 Breast Cancer 20 Lung Cancer 22 Cell-Free Tumor Testing 23 Cancer of Unknown Primary/Occult Neoplasm 23 Pancreatic Cancer 24 Prostate Cancer 25 Thyroid Cancer 26 Cancer Screening 26 Indeterminate Thyroid Nodules 26 Colorectal Cancer Screening 28 Professional Society Guidelines 29 PROPRIETARY Guidelines (...) . All Rights Reserved. 6 ? Hepatobiliary cancer ? Kidney cancer ? Malignant pleural mesothelioma ? Merkle cell carcinoma ? Multiple myeloma ? Neuroendocrine and adrenal tumors - including gastrointestinal and lung ? Non-epithelial ovarian cancers or borderline epithelial tumors (low malignant potential) ? Occult primary ? Pancreatic cancer ? Prostate cancer - post-diagnosis gene expression classifiers ? Skin cancer - basal and squamous cell ? Small cell lung cancer ? T-cell lymphoma: cutaneous

2020 AIM Specialty Health

2. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

as outlined in the criteria in the NCCN ® Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ), Prostate Cancer Early Detection. Confirmed Malignancy Gene expression or molecular profiling assays for confirmed prostate tumors are not medically necessary. Thyroid Cancer Confirmed or Highly-Suspected Thyroid Cancer BRAF V600E mutation analysis is medically necessary in cases with confirmed or highly-suspected follicular thyroid carcinoma, papillary thyroid carcinoma, medullary thyroid carcinoma (...) Use Criteria 3 National Comprehensive Cancer Network® (NCCN®) Criteria* 4 Polycythemia Vera 5 Essential Thrombocythemia or Thrombocytosis 5 Primary Myelofibrosis 5 Breast Cancer 6 Cancer of Unknown Primary/Occult Neoplasm 7 Prostate Cancer 7 Screening 7 Confirmed Malignancy 7 Thyroid Cancer 7 Confirmed or Highly-Suspected Thyroid Cancer 7 Cytologically Indeterminate Thyroid Nodule 7 Colorectal Cancer Screening 8 CPT Codes 8 Background 12 Myeloproliferative Disorders 12 Polycythemia Vera 12

2019 AIM Specialty Health

3. Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma. (Abstract)

Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma. To study if prostatic ductal adenocarcinoma (PDA) controlled by Grade Group (GG), PSA, and tumor volume (TV) is an independent predictor of adverse radical prostatectomy (RP) outcomes.One-hundred and twenty-eight PDA and 1141 acinar continuous RPs were studied. Each tumor nodule (TN (...) ) was individually graded, staged, and its TV measured. Univariate analysis (UVA) identified features associated with lymph node metastasis (LN+), extraprostatic extension (EPE), positive surgical margins (SM+), and seminal vesicle invasion (SV+). We then assessed PDA effect on RP outcomes in a multivariate analysis (MVA).In 127 cases PDA was present in 1 TN and no TN was pure PDA. One-hundred and twenty-three cases had PDA in TNs with highest grade, stage, and TV. Patients with PDA were older (65 vs 63 years, P

2020 Urology

4. Management of Female Malignant Ovarian Germ Cell Tumours

, Pontes EM, Dos Santos Aguiar S, Mastellaro MJ, Melaragno R, et al. Cisplatin and etoposide in childhood germ cell tumor: Brazilian pediatric oncology society protocol GCT-91. J Clin Oncol 2009;27:1297–303. 19. Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer 2011;105:493–7. 20. Liu Q, Ding X, Yang J, Cao D, Shen K, Lang J, et al. The significance of comprehensive (...) will be cured with chemotherapy at recurrence. 24,25 At present, there are insufficient data to recommend that women with stage Ic disease be offered surgery followed by surveillance alone. However, women with immature grade I or II teratomas could probably be considered for surveillance. Whether this would also be safe for women with stage Ic grade III disease, which frankly should be viewed as a malignant tumour that has not been completely © Royal College of Obstetricians and Gynaecologists 3 of 10

2016 Royal College of Obstetricians and Gynaecologists

5. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

Tumor Testing 10 Breast Cancer 10 Lung Cancer 12 Cell-Free Tumor Testing 13 Cancer of Unknown Primary/Occult Neoplasm 14 Prostate Cancer 14 Thyroid Cancer 15 Cancer Screening 15 Indeterminate Thyroid Nodules 15 Colorectal Cancer Screening 16 Professional Society Guidelines 18 Selected References 19 Revision History 20 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved. 3 Scope This document (...) • Prostate Cancer Early Detection • Soft Tissue Sarcoma • Lung Cancer See more specific criteria below for: • Myeloproliferative neoplasms • Breast cancer • Cell-Free Tumor Testing • Cancer of Unknown Primary/Occult NeoplasmProstate Cancer (confirmed, not screening) • Thyroid Cancer and Indeterminate Thyroid Nodules • Colorectal Cancer Screening Polycythemia Vera JAK2 mutation testing is medically necessary for the diagnosis of polycythemia vera when both of the following conditions are met: • Genetic

2017 AIM Specialty Health

6. Skene's Gland Adenocarcinoma: Borrowing from Prostate Cancer Experience for the Evaluation and Management of a Rare Malignancy. (Abstract)

Skene's Gland Adenocarcinoma: Borrowing from Prostate Cancer Experience for the Evaluation and Management of a Rare Malignancy. To determine if adenocarcinoma of the Skene's glands in women, which has a histological and immunohistochemical appearance similar to prostate cancer, can be evaluated and managed with the same tools we use for prostate cancer.Serum prostate specific antigen (PSA) kinetics, 3D multiparametric (MP) magnetic resonance imaging (MRI), fluciclovine F-18 positron emission (...) of Skene's gland adenocarcinoma, we can employ many of the tools at our disposal for the evaluation and management of prostate cancer to benefit the women found to have this malignancy.Copyright © 2020. Published by Elsevier Inc.

2020 Urology

7. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

the Committee, issued a positive opinion for granting a marketing authorisation to Tookad on 14 September 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy = 10 years and: - Clinical stage T1c or T2a, - Gleason Score = 6, based on high-resolution biopsy strategies, - PSA = 10 ng/mL, - 3 positive cancer cores (...) Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report

2017 European Medicines Agency - EPARs

8. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. Full Text available with Trip Pro

Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. To evaluate the presence of circulating tumour cells (CTCs) at different stages of prostate cancer using the AdnaTest® ProstateCancerDetect kit (Qiagen). Moreover, we aimed to assess the expression of transcripts that are specific for cancer stem cells (AdnaTest StemCell) and epithelial-mesenchymal transition (EMT) in CTCs (AdnaTest EMT), as well as additional genes (...) marker.AdnaTest ProstateCancerDetect exhibits positive results mainly in patients with metastatic disease. Expression of AR and TYMS are frequent events in CTCs of patients with advanced disease, whereas c-met and c-kit gene expression is seen in only a small proportion of patients. The implications of these results for the use of CTC analysis as a decision factor for personalised treatment strategies in advanced prostate cancer remain to be determined.© 2018 The Authors BJU International © 2018 BJU

2018 BJU international

9. A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies

for elective surgical resection, disease does not require immediate therapy, and there is NO approved/ standard therapy available that is shown to prolong overall survival. ECOG performance status of 0 or 1. Must have a tumor lesion that is amenable to biopsy, and willing to undergo biopsy. Willing to provide tissue and blood samples for research. Exclusion Criteria: The following solid tumors are NOT eligible: Primary brain tumor, Ocular melanoma, Head and neck cancer, Breast cancer, Prostate cancer (...) , Testicular cancer, and Stage III rectal cancer. Any active malignancy within 3 years prior, except: Adequately treated basal cell or squamous cell skin cancer, or early stage cancers (carcinoma in situ or stage 1) treated with curative intent. Any uncontrolled intercurrent illness, including but not limited to: Symptomatic congestive heart failure, Unstable angina pectoris or coronary angioplasty or stenting within 6 months prior to enrollment, Cardiac arrhythmia, Psychiatric illness or social situations

2018 Clinical Trials

10. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Full Text available with Trip Pro

of disease. There was no significant difference noted with regard to noncancer deaths for any studied solid tumor. Use of surgery (evaluated in patients with nonmetastatic tumors, and in addition matched by disease stage) did not differ between cases and controls, except for fewer prostatectomies being noted among patients with myeloma (odds ratio, 0.56; 95% confidence interval, 0.42-0.74).The results of the current study support curative treatment approaches to secondary cancers among patients (...) Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Therapeutic advances have extended survival for patients with myeloma, who may develop secondary cancers.Using the population-based Surveillance, Epidemiology, and End Results registry (2004-2015), the authors examined the characteristics, overall and cause-specific survival, and cumulative incidence function of cancer-related death among patients with myeloma with secondary cancers

2018 Cancer

11. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population. Full Text available with Trip Pro

multi-stage approach to identify the polymorphisms associated with prostate cancer and use them as screening factors. Screening tests can identify people who may have a chance of developing the disease before detection and any symptoms.The case-control study included 103 cases (prostate adenocarcinoma) and 100 controls (benign prostatic hyperplasia). Tetra-primer ARMS-PCR was used to genotyping of each participant. A Multi-stage approach was used for efficient genomic study. In this method (...) Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population. Prostate cancer is one of the five common cancers and has the second incidence rate and the third mortality rate in Iranian population. The purpose of this study was to evaluate the association of rs16901979, rs4242382 and rs1447295 on 8q24 locus, rs2735839 (KLK3 gene) and rs721048 (EHBP1 gene) with prostate adenocarcinoma through

2020 BMC Medical Genetics

12. How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study. (Abstract)

How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study. To assess the accuracy of multiparametric magnetic resonance imaging (mpMRI) for the detection of significant prostate cancer in men undergoing radical prostatectomy (RP) in an Australian multicentre setting, and to assess concordance between mpMRI and RP for local tumour staging and index lesion locations.Men who underwent mpMRI within 12 (...)  months of RP between January 2013 and August 2016 at three Australian sites were included (Central Coast, NSW, St Vincents Hospital, Melbourne, Vic., and Bendigo Hospital, Vic.). The results of mpMRI were compared with the final RP specimen to analyse the performance of mpMRI for significant prostate cancer detection, index lesion localization, prediction of T3 disease and lymph node metastasis. A comparison between mpMRI cases performed using the technical and reporting specifications of Prostate

2019 BJU international

13. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human (...) -stage HER2-overexpressed/amplified breast cancer at high risk of recurrence (node positive and within 1 year of completion of prior adjuvant trastuzumab based therapy). 2.1.2. Epidemiology, screening tools/prevention Breast cancer is the most frequently diagnosed malignancy in women and the leading cause of cancer mortality in women worldwide. In 2012, the estimated age-adjusted annual incidence of breast cancer Assessment report EMA/CHMP/525204/2018 Page 9/169 in 40 European countries was 94.2/100

2018 European Medicines Agency - EPARs

14. Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank Full Text available with Trip Pro

Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate (...) cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate

2017 Biomarkers in cancer

15. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer Full Text available with Trip Pro

Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer Connexin 43, a gap junction protein, coordinates cell-to-cell communication and adhesion. Altered Connexin 43 expression associated with cancer development and progression. In this study, we assessed Connexin 43 expression for association with clinicopathological features and biochemical recurrence of prostate cancer after radical prostatectomy. Pathological (...) specimens were collected from 243 patients who underwent radical prostatectomy and from 60 benign prostatic hyperplasia (BPH) patients to construct tissue microarrays and immunohistochemical analysis of Connexin 43 expression. Kaplan-Meier curves and multivariable Cox proportion hazard model were performed to associate Connexin 43 expression with postoperative biochemical recurrence-free survival (BFS). Connexin 43 expression was significantly reduced or lost in tumor tissues compared to that of BPHs

2016 Oncotarget

16. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. (Abstract)

Controlled Trial 2016 12 21 United States J Urol 0376374 0022-5347 731DCA35BT Diethylstilbestrol AIM IM J Urol. 2017 Feb;197(2S):S140-S141 28010973 Adenocarcinoma mortality pathology therapy Aged Cause of Death Chemotherapy, Adjuvant methods Diethylstilbestrol therapeutic use Follow-Up Studies Humans Male Neoplasm Grading Neoplasm Staging Orchiectomy Prognosis Prospective Studies Prostate pathology Prostatectomy Prostatic Neoplasms mortality pathology therapy Survival Rate Treatment Outcome Arduino Lino (...) Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. 28012760 2019 04 05 2019 04 05 1527-3792 197 2S 2017 02 The Journal of urology J. Urol. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. S134-S139 S0022-5347(16)31652-4 10.1016/j.juro.2016.10.099 Gleason Donald F DF Mellinger George T GT Veterans Administration Cooperative Urological Research Group eng Journal Article Randomized

2019 The Journal of urology Controlled trial quality: uncertain

17. Metachronous triple primary neoplasms with primary prostate cancer, lung cancer, and colon cancer: A case report. Full Text available with Trip Pro

of the lung showed moderately differentiated adenocarcinoma with epidermal rowth factor receptor exon 21 mutation.Metachronous triple primary neoplasms with primary prostate cancer, lung cancer and colon cancer.The patient underwent surgical resection of the right upper lobe of the lung, postoperative stage was T1bN0M0 (stage IA). After 8 cycles of chemotherapy with modified FOLFOX6 regimen (oxaliplatin 85 mg/m, leucovorin 400 mg/m, 5-fluorouracil 400 mg/m on day 1, followed by 5-fluorouracil 2400 mg/m (...) Metachronous triple primary neoplasms with primary prostate cancer, lung cancer, and colon cancer: A case report. Multiple primary neoplasms (MPNs) are rare. Most MPNs are double, and triple primary neoplasms are extremely rarer. Here, we describe a case of a 66-year-old man diagnosed with metachronous triple primary neoplasms with primary prostate cancer, lung cancer and colon cancer.The patient complained of dysuria in January 2015, and he underwent transurethral resection of the prostate

2018 Medicine

18. FOXP3<sup>+</sup> regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Full Text available with Trip Pro

FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. The tumor promoting or counteracting effects of the immune response to cancer development are thought to be mediated to some extent by the infiltration of regulatory T cells (Tregs ). In the present study we evaluated the prevalence of Treg populations in stromal and epithelial compartments (...) of normal, post atrophic hyperplasia (PAH), prostatic intraepithelial neoplasia (PIN), and tumor lesions in men with and without prostate cancer.Study subjects were 102 men consecutively diagnosed with localized prostate cancer undergoing radical prostatectomy and 38 men diagnosed with bladder cancer undergoing cystoprostatectomy without prostate cancer at the pathological examination. Whole mount sections from all patients were evaluated for the epithelial and stromal expression of CD4+ Tregs and CD8

2017 Prostate

19. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. (Abstract)

Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. Intraductal carcinoma of the prostate (IDC-P) has a poor prognosis and is thought to be completely resistant to current therapies, including androgen deprivation therapy (ADT). However, to date, there are no data showing direct evidence of such resistance.We retrospectively evaluated 145 patients with high-risk prostate cancer who underwent (...) radical prostatectomy (RP) with neoadjuvant ADT between 1991 and 2005. All patient data were collected from slides prepared from needle biopsy (NB) samples of prostate tissue and RP specimens. Data were analyzed in terms of serum level of prostate specific antigen (PSA), Gleason score of NB samples, clinical T stage, the positive cancer core rate, maximum cancer extension rate, presence of Gleason pattern 5, and presence of IDC-P in both NB samples and RP specimens.The median initial PSA was 33.2 ng

2020 Prostate

20. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Full Text available with Trip Pro

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. DNA repair gene mutations are present in 8-10% of localized prostate cancers. It is unknown whether this is influenced by clinicopathologic factors.We interrogated localized prostate adenocarcinomas with tumor DNA sequencing information from the TCGA validated (n = 333) and Nature Genetics (n = 377) datasets. Homologous recombination (...) by clinical tumor or nodal stage. Among men with Gleason grade group ≥ 3 and clinical stage ≥ cT3, 21.3% (1 in 5) had a DNA repair mutation in any gene and 11.7% (1 in 9) had a mutation in ATM/BRCA1/2.The prevalence of pathogenic DNA repair gene alterations is enriched in men with advanced tumor stages and higher Gleason grade groups, with maximal enrichment observed in those with Gleason grade group ≥ 3 and clinical stage ≥ cT3 disease. This information can be used to guide eligibility criteria

2018 Prostate cancer and prostatic diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>